[go: up one dir, main page]

WO2003102159A3 - Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines - Google Patents

Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines Download PDF

Info

Publication number
WO2003102159A3
WO2003102159A3 PCT/US2003/017573 US0317573W WO03102159A3 WO 2003102159 A3 WO2003102159 A3 WO 2003102159A3 US 0317573 W US0317573 W US 0317573W WO 03102159 A3 WO03102159 A3 WO 03102159A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
nucleic acids
molecule target
therapeutic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/017573
Other languages
English (en)
Other versions
WO2003102159A2 (fr
Inventor
John P Ii Alsobrook
David W Anderson
Jason C Baumgartner
Constance Berghs
Ferenc L Boldog
Catherine E Burgess
Stacie J Casman
Elina Catterton
Mohanraj Dhanabal
Shlomit R Edinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to EP03817179A priority Critical patent/EP1590480A2/fr
Priority to AU2003256263A priority patent/AU2003256263A1/en
Priority to CA002488539A priority patent/CA2488539A1/fr
Publication of WO2003102159A2 publication Critical patent/WO2003102159A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003102159A3 publication Critical patent/WO2003102159A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouveaux polynucléotides isolés et polypeptides, ciblés par de petites molécules et codés par ces polynucléotides. Cette invention concerne également des anticorps se liant de façon immunospécifique à un nouveau polypeptide ciblé par de petites molécules ou tout dérivé, variant, mutant ou fragment de ce polypeptide, polynucléotide ou de cet anticorps ainsi que des méthodes dans lesquelles ce polypeptide ciblé par de petites molécules, ce polynucléotide et cet anticorps sont utilisés dans la détection et le traitement d'une large gamme d'états pathologiques. La présente invention concerne, plus spécifiquement, des méthodes d'utilisation de protéines exprimées de façon recombinante et/ou endogène dans diverses procédures de criblage à des fins d'identification d'anticorps thérapeutiques et de petites molécules thérapeutiques associés à des maladies. Cette invention concerne en outre des méthodes de recherche ainsi que des méthodes diagnostiques et thérapeutiques pour le diagnostic, le traitement et la prévention de troubles impliquant un de ces nouveaux acides nucléiques humains ou une de ces nouvelles protéines humaines.
PCT/US2003/017573 2002-06-04 2003-06-04 Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines Ceased WO2003102159A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03817179A EP1590480A2 (fr) 2002-06-04 2003-06-04 Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines
AU2003256263A AU2003256263A1 (en) 2002-06-04 2003-06-04 Novel proteins and nucleic acids encoding same
CA002488539A CA2488539A1 (fr) 2002-06-04 2003-06-04 Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines

Applications Claiming Priority (116)

Application Number Priority Date Filing Date Title
US38549002P 2002-06-04 2002-06-04
US38561502P 2002-06-04 2002-06-04
US38575502P 2002-06-04 2002-06-04
US60/385,615 2002-06-04
US60/385,755 2002-06-04
US60/385,490 2002-06-04
US38604102P 2002-06-05 2002-06-05
US60/386,041 2002-06-05
US38635702P 2002-06-06 2002-06-06
US38686402P 2002-06-06 2002-06-06
US38646502P 2002-06-06 2002-06-06
US38645902P 2002-06-06 2002-06-06
US38635502P 2002-06-06 2002-06-06
US38644702P 2002-06-06 2002-06-06
US60/386,447 2002-06-06
US60/386,355 2002-06-06
US60/386,864 2002-06-06
US60/386,459 2002-06-06
US60/386,357 2002-06-06
US60/386,465 2002-06-06
US38676902P 2002-06-07 2002-06-07
US38708302P 2002-06-07 2002-06-07
US38670102P 2002-06-07 2002-06-07
US38693102P 2002-06-07 2002-06-07
US38707802P 2002-06-07 2002-06-07
US38708102P 2002-06-07 2002-06-07
US60/387,081 2002-06-07
US60/387,083 2002-06-07
US60/387,078 2002-06-07
US60/386,701 2002-06-07
US60/386,931 2002-06-07
US60/386,796 2002-06-07
US38742902P 2002-06-10 2002-06-10
US38786602P 2002-06-10 2002-06-10
US38754002P 2002-06-10 2002-06-10
US60/387,866 2002-06-10
US60/387,429 2002-06-10
US60/387,540 2002-06-10
US38760602P 2002-06-11 2002-06-11
US38761002P 2002-06-11 2002-06-11
US38766802P 2002-06-11 2002-06-11
US38785902P 2002-06-11 2002-06-11
US38769602P 2002-06-11 2002-06-11
US38765902P 2002-06-11 2002-06-11
US60/387,696 2002-06-11
US60/387,659 2002-06-11
US60/387,859 2002-06-11
US60/387,668 2002-06-11
US60/387,606 2002-06-11
US60/387,610 2002-06-11
US38793402P 2002-06-12 2002-06-12
US38843202P 2002-06-12 2002-06-12
US38809602P 2002-06-12 2002-06-12
US38847902P 2002-06-12 2002-06-12
US38802202P 2002-06-12 2002-06-12
US38796002P 2002-06-12 2002-06-12
US60/388,096 2002-06-12
US60/387,960 2002-06-12
US60/388,022 2002-06-12
US60/388,432 2002-06-12
US60/387,934 2002-06-12
US60/388,479 2002-06-12
US38912302P 2002-06-13 2002-06-13
US60/389,123 2002-06-13
US38912002P 2002-06-14 2002-06-14
US38914602P 2002-06-14 2002-06-14
US60/389,120 2002-06-14
US60/389,146 2002-06-14
US38974202P 2002-06-17 2002-06-17
US60/389,742 2002-06-17
US38960402P 2002-06-18 2002-06-18
US38988402P 2002-06-18 2002-06-18
US60/389,884 2002-06-18
US60/389,604 2002-06-18
US39000602P 2002-06-19 2002-06-19
US39014402P 2002-06-19 2002-06-19
US39020902P 2002-06-19 2002-06-19
US60/390,209 2002-06-19
US60/390,006 2002-06-19
US60/390,144 2002-06-19
US39172602P 2002-06-25 2002-06-25
US60/391,726 2002-06-25
US40162802P 2002-08-06 2002-08-06
US60/401,628 2002-08-06
US40226802P 2002-08-09 2002-08-09
US60/402,268 2002-08-09
US40282202P 2002-08-12 2002-08-12
US60/402,822 2002-08-12
US40345802P 2002-08-13 2002-08-13
US60/403,458 2002-08-13
US40373202P 2002-08-15 2002-08-15
US40361702P 2002-08-15 2002-08-15
US60/403,732 2002-08-15
US60/403,617 2002-08-15
US40618202P 2002-08-26 2002-08-26
US60/406,182 2002-08-26
US41008502P 2002-09-12 2002-09-12
US60/410,085 2002-09-12
US41050502P 2002-09-13 2002-09-13
US60/410,505 2002-09-13
US41295502P 2002-09-23 2002-09-23
US60/412,955 2002-09-23
US41519502P 2002-09-30 2002-09-30
US60/415,195 2002-09-30
US42071802P 2002-10-23 2002-10-23
US42062702P 2002-10-23 2002-10-23
US60/420,627 2002-10-23
US60/420,718 2002-10-23
US42085202P 2002-10-24 2002-10-24
US60/420,852 2002-10-24
US42275002P 2002-10-31 2002-10-31
US60/422,750 2002-10-31
US42309502P 2002-11-01 2002-11-01
US60/423,095 2002-11-01
US42374802P 2002-11-05 2002-11-05
US60/423,748 2002-11-05

Publications (2)

Publication Number Publication Date
WO2003102159A2 WO2003102159A2 (fr) 2003-12-11
WO2003102159A3 true WO2003102159A3 (fr) 2005-08-11

Family

ID=34831606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017573 Ceased WO2003102159A2 (fr) 2002-06-04 2003-06-04 Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines

Country Status (1)

Country Link
WO (1) WO2003102159A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415056D0 (en) * 2004-07-05 2004-08-04 Celltech R&D Ltd A protein involved in carcinoma
EP1762575A1 (fr) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (fr) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
EP2371864A1 (fr) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
CN112194944B (zh) * 2020-10-10 2021-12-17 浙江圣力邦漆业有限公司 一种丙烯酸涂料制备工艺
CN115518161B (zh) * 2022-11-02 2023-11-10 天津医科大学总医院 Zip1作为癫痫治疗靶标的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022131A2 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022131A2 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive

Also Published As

Publication number Publication date
WO2003102159A2 (fr) 2003-12-11

Similar Documents

Publication Publication Date Title
WO2003000842A3 (fr) Nouvelles proteines et acides nucleiques codant pour de telles proteines
WO2004000997A3 (fr) Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation
WO2003040325A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
WO2002081498A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2003010327A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2004015060A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation associees
WO2003083046A3 (fr) Nouvelles proteines et acides nucleiques codant pour de telles proteines
WO2002081510A3 (fr) Proteines, polynucleotides codant pour celles-ci et methodes d'utilisation
WO2003023001A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
WO2003064628A3 (fr) Mandrin a vide faisant intervenir un materiau fritte et procede de fabrication
WO2003029424A3 (fr) Nouvelle proteines et acides nucleiques codant celles-ci
WO2002000691A3 (fr) Nouveaux polynucleotides et polypeptides codes par ceux-ci
WO2002072757A3 (fr) Proteines et acides nucleiques codant pour ces proteines
WO2002055704A3 (fr) Proteines, polynucleotides codant pour elles et procedes d'utilisation correspondants
WO2003102159A3 (fr) Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines
WO2002079398A3 (fr) Polypeptides therapeutiques, les acides nucleiques les codant et leurs procedes d'utilisation
WO2003078572A3 (fr) Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et procedes d'utilisation
WO2002099116A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et procedes d'utilisation
WO2003022998A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation correspondantes
WO2001074851A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2003057854A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2003040329A3 (fr) Polypeptides therapeutiques, acides nucleiques les codant et procedes d'utilisation correspondant
WO2004048512A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2001046231A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
EP1792912A3 (fr) Oscillateur avec fréquence contrôlée par tension pour la détection de la position de rotor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2003256263

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2488539

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003817179

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003817179

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP